{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

BETA-Blockers in Cardiovascular Therapy: A Comparative Analysis survey of Their Efficacy WIth CAD and Hypertension managEment (BETA WISE)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. Which class of drug do you most prefer for managing hypertension, considering that hypertension leads to structural and functional alterations in the heart, which are asymptomatic at an early stage but potent risk factors for subsequent cardiovascular events such as heart failure (HFpEF or HFrEF), atrial fibrillation (AF), coronary artery disease (CAD), sudden death, and stroke? *

  2. When comparing beta-blockers with other blood pressure-lowering drugs, studies suggest they are almost equivalent in preventing major cardiovascular events. What is your level of agreement with this finding? *

  3. Considering the pharmacological nuances, do you believe that beta-1 selectivity plays a significant role in effectively managing blood pressure? *

  4. How do you determine the most appropriate beta-blocker for a patient with multiple cardiovascular conditions? *
  5. Which beta-blocker do you prefer for ischemic heart disease? *

  6. For post-myocardial infarction cases involving arrhythmias, which beta-blocker do you prefer? And mention the reason for the same *
  7. Which beta-blocker do you prefer for acute coronary syndrome? *

  8. For managing hypertension in patients with an elevated resting heart rate of over 80 bpm, which beta-blocker do you most prefer, considering its effectiveness in controlling heart rate and blood pressure to reduce cardiovascular risk factors? *

  9. Describe your approach to switch beta-blockers in patients who experience side effects. *
  10. In cases of atrial fibrillation involving prevention, rhythm control, or heart rate control, which beta-blocker do you prefer? *

  11. What factors do you consider when prescribing beta-blockers to elderly patients? *
  12. For managing hypertension in patients with chronic obstructive pulmonary disease (COPD), which beta-blocker do you prefer? *

  13. For managing anxiety disorders, which beta-blocker do you prefer? *

  14. Which beta-blocker do you find most effective in providing strong control over both resting and exercise-induced heart rates? *

  15. How do you address concerns from patients regarding potential side effects of beta- blockers? *
  16. In your experience, which beta-blocker is metabolically neutral (does not disturb blood sugar or lipid levels) in patients with both hypertension and coronary artery disease (CAD)? Give out the reason for the same *
  17. For hypertensive patients who are smokers, which beta-blocker is your preferred choice? *

  18. Do you agree with the statement that coronary plaque disruption is closely related to a high heart rate, which can be reversed by beta-blockade? (Beta-blockers also reduce coronary artery wall stress, thereby appearing to stabilize the plaque) *

  19. In what ways do you monitor the effectiveness of beta-blocker therapy in your patients? *
  20. Do you believe that diastolic hypertension in younger or middle-aged patients, often linked to central obesity? *

  21. Can you share an example of a challenging case where beta-blocker therapy was critical to patient management? *
  22. Do you agree that the principal goals of managing coronary artery disease (CAD) include augmenting coronary artery blood flow and limiting myocardial oxygen demands? *

  23. What is your protocol for managing beta-blocker withdrawal in patients who need to discontinue therapy? *
  24. Which beta-blocker do you believe has the strongest antihypertensive properties? *

  25. What are the primary differences in the mechanism of action between Metoprolol and Bisoprolol? *

  26. In your clinical practice, which age group of patients most frequently receives Metoprolol? *

  27. How do you balance the use of beta-blockers with other medications in polypharmacy patients? *
  28. In your clinical practice, which age group of patients most frequently receives Bisoprolol? *

  29. How do you find the tolerability of Metoprolol in your patients? *

  30. What role do you believe patient lifestyle plays in the effectiveness of beta-blocker therapy? *
  31. For patients with microvascular angina and abnormal microvascular function, which beta-blocker do you prefer? *

  32. How do you educate patients about the importance of adherence to beta-blocker therapy? *
  33. Within 24 hours of presentation with non-ST-elevation myocardial infarction (NSTEMI), which beta-blocker do you prefer the most? *

  34. Within 24 hours of presentation with ST-elevation myocardial infarction (STEMI), which beta-blocker do you prefer the most? *

  35. In your experience, which beta-blocker has improved in-hospital mortality, rates of reinfarction, and rates of cardiogenic shock the most? *

  36. According to your experience, which beta-blocker provides ease of titration? *

  37. What are your considerations when prescribing beta-blockers to patients with comorbid mental health conditions? *
  38. Have you experienced bradycardia in patients using beta-blockers? *

  39. Which beta-blockers have you used when you observed bradycardia in your patients? *

  40. How has recent research/guideline recommendations influenced your choice of beta- blockers in clinical practice? *
  41. Have you experienced worsening of COPD conditions in your hypertension with CAD patients while prescribing extended-release formulations of Metoprolol? *

  42. For which indication do you prefer the combination of a beta-blocker and an ARB? *

  43. In comparison with the Bisoprolol + Telmisartan fixed-dose combination (FDC), what clinical advantage is provided by the Metoprolol + Telmisartan combination? *

  44. Do you agree that Metoprolol + Telmisartan FDC is a useful tool in the expanding therapeutic armamentarium to address the unmet need in hypertension and CAD? *

  45. Do you agree that Metoprolol + Telmisartan FDC is a useful tool in the expanding therapeutic armamentarium to address the unmet need in heart failure? Give me the reason if you agree/disagree *
  46. What are the most common barriers you face when initiating beta-blocker therapy in your patients? *
  47. Do you feel that Metoprolol is the most extensively studied beta-blocker in patients with hypertension and ischemic heart disease (IHD)? *

  48. How do you approach the treatment of beta-blocker-induced bradycardia in your patients? *
  49. Which beta-blocker do you prefer for elderly patients with hypertension and isolated systolic hypertension? *

  50. Considering the management of hypertension with chronic kidney disease, which beta-blocker do you prefer? *